Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 May 2020Website:
http://lyratherapeutics.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:35:55 GMTDividend
Analysts recommendations
Institutional Ownership
LYRA Latest News
Lyra Therapeutics, Inc. (LYRA) reported a quarterly loss of $0.35 per share, which was higher than the Zacks Consensus Estimate of a loss of $0.26 per share. This is an improvement from the loss of $0.44 per share reported in the same quarter last year.
Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Lyra Therapeutics (LYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
The consensus price target hints at a 101.8% upside potential for Lyra Therapeutics (LYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Lyra Therapeutics has two product candidates in clinical trials for Chronic rhinosinusitis (CRS) patients. Both candidates, LYR-210 and LYR-220, show promising efficacy data, with LYR-210 in phase 3 trials and LYR-220 in phase 2 trials. Lyra has a market cap of $190mn and enough cash to sustain operations until 2025, but more cash would be desirable.
Lyra Therapeutics' LYR-220 shows promise in addressing chronic rhinosinusitis, targeting a patient demographic that doesn't respond to current treatments. The company maintains a stable balance sheet with a 24-month cash runway and a healthy asset-to-liability ratio. The upcoming ENLIGHTEN 1 Phase 3 trial could significantly impact the company's clinical and financial trajectory.
Lyra (LYRA) gains on positive data from mid-stage study of LYR-220, treating patients with chronic rhinosinusitis who have had ethmoid sinus surgery.
What type of business is Lyra Therapeutics?
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
What sector is Lyra Therapeutics in?
Lyra Therapeutics is in the Healthcare sector
What industry is Lyra Therapeutics in?
Lyra Therapeutics is in the Biotechnology industry
What country is Lyra Therapeutics from?
Lyra Therapeutics is headquartered in United States
When did Lyra Therapeutics go public?
Lyra Therapeutics initial public offering (IPO) was on 01 May 2020
What is Lyra Therapeutics website?
https://lyratherapeutics.com
Is Lyra Therapeutics in the S&P 500?
No, Lyra Therapeutics is not included in the S&P 500 index
Is Lyra Therapeutics in the NASDAQ 100?
No, Lyra Therapeutics is not included in the NASDAQ 100 index
Is Lyra Therapeutics in the Dow Jones?
No, Lyra Therapeutics is not included in the Dow Jones index
When does Lyra Therapeutics report earnings?
The next expected earnings date for Lyra Therapeutics is 08 August 2024